SCHEMBL3600229

SCHEMBL3600229

CCCCN(CCCC)CCC(=O)N(CC(=O)O)c1ccc(C(=O)c2c(C)c(OC)c3ccccn23)cc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.38
ATM Q13315 2/20 0.38
GAA P10253 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MAPT P10636 4/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.33
TP53 P04637 1/20 0.33
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
BCHE P06276 1/20 0.32
ACHE P22303 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598724 0.93 NPC1 (0.39) NPC1ATMGAARXFP1MAPT
Hydrochloric Acid SCHEMBL3596333 0.92 NPC1 (0.39) NPC1ATMGAARXFP1MAPT
SCHEMBL3595468 0.91 MAPT (0.34) NPC1ATMGAARXFP1MAPT
SCHEMBL3601517 0.86 NPC1 (0.36) NPC1ATMGAARXFP1MAPT
SCHEMBL3592666 0.86 NPC1 (0.36) NPC1ATMGAARXFP1MAPT
Hydrochloric Acid SCHEMBL3593319 0.85 NPC1 (0.35) NPC1ATMGAARXFP1MAPT
Hydrochloric Acid SCHEMBL3601197 0.80 NPC1 (0.41) NPC1ATMGAARXFP1MAPT
SCHEMBL3597898 0.79 NPC1 (0.35) NPC1ATMGAARXFP1MAPT
Hydrochloric Acid SCHEMBL3602933 0.79 NPC1 (0.40) NPC1ATMGAARXFP1MAPT
SCHEMBL3597180 0.77 MAPT (0.34) NPC1ATMGAARXFP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803811-B2 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2010-09-28 US disclosed
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them SANOFI-AVENTIS (FR) 2009-01-22 US disclosed
US-7442708-B2 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI-AVENTIS (FR) 2008-10-28 US disclosed
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same SANOFI (FR) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203126-A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same FGFR3, FGFR1, NTRK3 NPC1 2040/4885ATM 3197/4885GAA 4090/4885
US-20090023770-A1 Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them FGF2, FGF1, FGFR1 NPC1 2760/4885ATM 3401/4885GAA 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.